Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amphastar Pharma
(NQ:
AMPH
)
46.02
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amphastar Pharma
< Previous
1
2
3
4
5
Next >
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Beats Revenue for Q2 2024
August 07, 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
June 24, 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.
Via
InvestorPlace
Why the growth investor may take a look at NASDAQ:AMPH.
June 05, 2024
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
May 16, 2024
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Exploring NASDAQ:AMPH's growth characteristics.
May 15, 2024
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) showing high EPS and FCF growth while beating expectations
Via
Chartmill
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
May 08, 2024
AMPH stock results show that Amphastar Pharma beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
NASDAQ:AMPH, an undervalued stock with good fundamentals.
March 12, 2024
AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH): good value for what you're paying.
Via
Chartmill
Delving into NASDAQ:AMPH's Growth Prospects.
February 28, 2024
Should you consider AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) for growth investing?
Via
Chartmill
Earnings Outlook For Amphastar Pharma
February 27, 2024
Via
Benzinga
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
May 01, 2024
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
April 10, 2024
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections...
Via
Benzinga
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
February 14, 2024
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?
Via
Chartmill
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
February 13, 2024
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
February 07, 2024
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.
Via
Chartmill
Unlocking the Growth Potential of NASDAQ:AMPH.
January 23, 2024
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics.
Via
Chartmill
NASDAQ:AMPH is not too expensive for the growth it is showing.
January 17, 2024
Looking for growth without the hefty price tag? Consider NASDAQ:AMPH.
Via
Chartmill
Why NASDAQ:AMPH is Poised for High Growth.
January 16, 2024
Exploring AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH)'s growth characteristics.
Via
Chartmill
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
February 05, 2024
As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.
Via
InvestorPlace
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
January 23, 2024
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Despite its impressive fundamentals, NASDAQ:AMPH remains undervalued.
January 23, 2024
For those who appreciate value investing, AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is a compelling option with its solid fundamentals.
Via
Chartmill
What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition
January 19, 2024
Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion...
Via
Benzinga
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
January 17, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.
Via
Benzinga
Why AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) qualifies as a high growth stock.
January 02, 2024
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?
Via
Chartmill
Should you consider NASDAQ:AMPH for growth investing?
December 26, 2023
Is AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) suited for growth investing?
Via
Chartmill
Cassava Sciences Stock Continues Showing Rising Relative Strength
January 16, 2024
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.
Via
Investor's Business Daily
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Cytokinetics Stock Jumps To Higher RS Level; Shoots Up On Heart Drug Study
December 28, 2023
On Thursday, Cytokinetics stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 99 from 89 the day before.
Via
Investor's Business Daily
Recursion Pharm Showing Market Leadership As Biotech Stocks Shoot Higher
December 26, 2023
On Tuesday, Recursion Pharm stock reached a key technical benchmark, seeing its Relative Strength Rating jump to 91 from 88 the day before.
Via
Investor's Business Daily
3 Reasons Why Amphastar Is a Great Growth Stock
December 26, 2023
Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great...
Via
Talk Markets
3 Stocks at the Forefront of Medical Innovation
December 25, 2023
Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way.
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.